BFC Planning’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$67.3K Buy
228
+3
+1% +$791 ﹤0.01% 1415
2026
Q2
$51K Buy
+225
New +$40.1K ﹤0.01% 1539
2025
Q2
– Sell
-41
Closed -$6.17K – 2707
2025
Q1
$6.17K Hold
41
– – ﹤0.01% 1952
2024
Q4
$7.57K Hold
41
– – ﹤0.01% 1877
2024
Q3
$8.08K Buy
+41
New +$8.52K ﹤0.01% 1838

Other funds holding CRL

BFC Planning's CRL Position: Q3 2026 in Review

BFC Planning increased its Charles River Laboratories (CRL) stake by 1.3% in Q3 2026, buying an estimated $791 and bringing the position to 228 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

BFC Planning first reported a position in CRL in Q3 2024 and has held it in 5 quarters since. 526 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • BFC Planning held 228 shares of Charles River Laboratories worth $67.3K as of Q3 2026.
  • BFC Planning bought 3 Charles River Laboratories shares in Q3 2026, an estimated $791.
  • Charles River Laboratories made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1415 holding.
  • BFC Planning first reported a position in Charles River Laboratories in Q3 2024 and has held it in 5 quarters since.
  • 526 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.